Efficacy of sacituzumab govitecan in triple-negative breast cancer with hepatic visceral crisis: a case report

Triple-negative breast cancer (TNBC) is recognized as the most aggressive molecular subtype of breast cancer (BC). The liver is a common site of distant metastasis in BC, and hepatic involvement is associated with accelerated therapeutic resistance and increased mortality risk. Although sacituzumab...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jiaqi Ye, Jiaang Ye, Huijuan He, Zhongyu Jiang, Yan Wang, Li Wang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-02-01
Saila:	Frontiers in Oncology
Gaiak:	antibody-drug conjugate hepatic visceral crisis partial response sacituzumab govitecan triple-negative breast cancer
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1790357/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!